24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
Corporate
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Gilead
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
Corporate
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
22:21
Israel faces a new push to shut it out of the EU’s flagship research program
21:33
Nice cuts 500 jobs, but investors may be looking for much deeper changes
20:49
Air Canada returns to Israel with a 30% price increase
20:31
The dollar has reached a six-month high against the shekel. What is driving the move?
More stories
Buzz
Most popular
Daily
Weekly
1
From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits
2
ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years
3
Nice to lay off 500 employees as it struggles to navigate the AI transition
4
Israeli digital health company TailorMed acquired in $250 million deal
5
After years of delays, IDF prepares to deploy Elbit’s new Ro'em artillery systems
More news
Gilead
6 stories about Gilead
Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23
|
Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall
16.01.18
|
Zohar Shahar Levy
Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights
CTech’s Daily Israeli Tech News Roundup
10.12.17
|
CTech
Backlash against Trump’s Jerusalem declaration has reached Israeli tech. AmTrust is planning a listing on Tel Aviv Stock Exchange. Teva’s stock is up following news of more layoffs.
Generic Focus made Kite Pharma Founder Leave Teva
13.11.17
|
Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
Meet Kite Pharma's CEO, the Man Bringing Hope to Hodgkin's Lymphoma Patients
30.08.17
|
Dror Reich
With two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?
Gilead To Buy Kite Pharma for $11.9 Billion
29.08.17
|
Dror Reich
The drug company is looking to diversify into cell therapy following declining hepatitis c drug sales